[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 291,165
  • Shares Outstanding, K 119,821
  • Annual Sales, $ 6,650 K
  • Annual Income, $ -136,320 K
  • EBIT $ -134 M
  • EBITDA $ -124 M
  • 60-Month Beta 2.54
  • Price/Sales 43.09
  • Price/Cash Flow N/A
  • Price/Book 1.82

Options Overview Details

View History
  • Implied Volatility 154.83% (+5.23%)
  • Historical Volatility 65.07%
  • IV Percentile 29%
  • IV Rank 8.84%
  • IV High 1,257.44% on 11/18/25
  • IV Low 47.96% on 08/26/26
  • Expected Move (DTE 16) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 5,339
  • Open Int (30-Day) 6,335
  • Expected Range 2.42 to 2.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.27
  • Number of Estimates 4
  • High Estimate $-0.26
  • Low Estimate $-0.28
  • Prior Year $-0.27
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.23 +7.85%
on 08/24/26
2.88 -16.49%
on 08/07/26
-0.05 (-1.84%)
since 07/31/26
3-Month
1.81 +32.69%
on 06/25/26
3.23 -25.54%
on 07/13/26
-0.16 (-6.42%)
since 06/02/26
52-Week
0.93 +157.63%
on 09/09/25
3.23 -25.54%
on 07/13/26
+1.38 (+133.50%)
since 09/02/25

Most Recent Stories

More News
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial...

FATE : 2.40 (-1.23%)
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated...

FATE : 2.40 (-1.23%)
Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics: Q2 Earnings Snapshot

FATE : 2.40 (-1.23%)
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with...

FATE : 2.40 (-1.23%)
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with...

FATE : 2.40 (-1.23%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...

FATE : 2.40 (-1.23%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...

FATE : 2.40 (-1.23%)
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited...

FATE : 2.40 (-1.23%)
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2...

FATE : 2.40 (-1.23%)
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...

FATE : 2.40 (-1.23%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.64
2nd Resistance Point 2.56
1st Resistance Point 2.50
Last Price 2.40
1st Support Level 2.35
2nd Support Level 2.27
3rd Support Level 2.21

See More

52-Week High 3.23
Last Price 2.40
Fibonacci 61.8% 2.35
Fibonacci 50% 2.08
Fibonacci 38.2% 1.81
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.